Hence then, the article about new phase 3 tremfya guselkumab results in ulcerative colitis show a 77 percent overall clinical response rate and early symptom improvement was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement )
Last updated :
Also on site :
- Sony’s Indian Version of ‘Who Wants to Be a Millionaire?’ Hosted by Amitabh Bachchan, Adds Google Gemini as AI Guide (EXCLUSIVE)
- Help! My Wife Turned Into a Religious Zealot and Spiraled to Her Death. Then Our Problems Really Started.
- AI unicorn Mercor acquires Deeptune after founder Brendan Foody backed the startup